These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 9251904

  • 1. Dopamine DA1 receptor agonist activity of YM435 in the canine renal vasculature.
    Yatsu T, Uchida W, Inagaki O, Tanaka A, Takenaka T.
    Gen Pharmacol; 1997 Aug; 29(2):229-32. PubMed ID: 9251904
    [Abstract] [Full Text] [Related]

  • 2. Renal effect of YM435, a new dopamine D1 receptor agonist, in anesthetized dogs.
    Yatsu T, Arai Y, Takizawa K, Kasai-Nakagawa C, Takanashi M, Uchida W, Inagaki O, Tanaka A, Asano M, Honda K, Takenaka T.
    Eur J Pharmacol; 1997 Mar 12; 322(1):45-53. PubMed ID: 9088869
    [Abstract] [Full Text] [Related]

  • 3. Hemodynamic characterization of YM435, a novel dopamine DA1 receptor agonist, in anesthetized dogs.
    Yatsu T, Takizawa K, Kasai-Nakagawa C, Uchida W, Tanaka A, Asano M, Honda K, Takenaka T.
    J Cardiovasc Pharmacol; 1997 Mar 12; 29(3):382-8. PubMed ID: 9125677
    [Abstract] [Full Text] [Related]

  • 4. Effect of YM435, a dopamine DA1 receptor agonist, in a canine model of ischemic acute renal failure.
    Yatsu T, Arai Y, Takizawa K, Kasai-Nakagawa C, Takanashi M, Uchida W, Inagaki O, Tanaka A, Takenaka T.
    Gen Pharmacol; 1998 Nov 12; 31(5):803-7. PubMed ID: 9809482
    [Abstract] [Full Text] [Related]

  • 5. Pharmacological and pharmacokinetic characteristics of YM435, a novel dopamine DA1-receptor agonist, in anaesthetized dogs.
    Yatsu T, Miyamoto I, Kaneko-Takanuki F, Watanabe T, Takenaka T.
    J Pharm Pharmacol; 1997 Sep 12; 49(9):892-6. PubMed ID: 9306257
    [Abstract] [Full Text] [Related]

  • 6. Characterization of the renal microvascular actions of a new dopaminergic (DA1) agonist, YM435.
    Takenaka T, Forster H, Epstein M.
    J Pharmacol Exp Ther; 1993 Mar 12; 264(3):1154-9. PubMed ID: 8095547
    [Abstract] [Full Text] [Related]

  • 7. Effects of YM435, a novel dopamine D1 receptor agonist, on pancreatic exocrine secretion in anesthetized dogs.
    Iwatsuki K, Ren LM, Chiba S.
    Eur J Pharmacol; 1992 Aug 06; 218(2-3):237-41. PubMed ID: 1425944
    [Abstract] [Full Text] [Related]

  • 8. Effect of YM435, a novel dopamine DA1 receptor agonist, in a canine model of acute congestive heart failure.
    Yatsu T, Arai Y, Sudoh K, Shibasaki M, Uchida W, Inagaki O, Tanaka A, Takenaka T.
    Gen Pharmacol; 1998 May 06; 30(5):733-7. PubMed ID: 9559326
    [Abstract] [Full Text] [Related]

  • 9. D-1 dopamine receptors mediate dopamine-induced pancreatic exocrine secretion in anesthetized dogs.
    Iwatsuki K, Horiuchi A, Ren LM, Chiba S.
    Hypertens Res; 1995 Jun 06; 18 Suppl 1():S173-4. PubMed ID: 8529053
    [Abstract] [Full Text] [Related]

  • 10. Relative DA1-dopamine-receptor agonist and alpha-adrenoceptor antagonist activity of fenoldopam in the anesthetized dog.
    Kohli JD, Glock D, Goldberg LI.
    J Cardiovasc Pharmacol; 1988 Jan 06; 11(1):123-6. PubMed ID: 2450250
    [Abstract] [Full Text] [Related]

  • 11. 4-(3,4-Dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline derivatives. II. Their renal vasodilation activity and structure-activity relationship.
    Anan H, Tanaka A, Tsuzuki R, Yokota M, Yatsu T, Fujikura T.
    Chem Pharm Bull (Tokyo); 1996 Oct 06; 44(10):1865-70. PubMed ID: 8904813
    [Abstract] [Full Text] [Related]

  • 12. A novel orally active dopamine (DA) prodrug TA-870. IV. Renal vasodilatory and negative chronotropic effects in anesthetized dogs: influence of DA1 and DA2 dopamine receptor selective antagonists.
    Nishiyama S, Yoshikawa M, Yamaguchi I.
    J Cardiovasc Pharmacol; 1991 Apr 06; 17(4):560-7. PubMed ID: 1711621
    [Abstract] [Full Text] [Related]

  • 13. Hemodynamic effects of selective dopamine receptor agonists in the rat and dog.
    Hieble JP, Owen DA, Harvey CA, Blumberg AL, Valocik RE, DeMarinis RM.
    Clin Exp Hypertens A; 1987 Apr 06; 9(5-6):889-912. PubMed ID: 2887313
    [Abstract] [Full Text] [Related]

  • 14. Synthesis, resolution, and renal vasodilation activity of novel DA1 agonists: 4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline derivatives.
    Anan H, Tanaka A, Tsuzuki R, Yokota M, Yatsu T, Honda K, Asano M, Fujita S, Furuya T, Fujikura T.
    Chem Pharm Bull (Tokyo); 1991 Nov 06; 39(11):2910-4. PubMed ID: 1839245
    [Abstract] [Full Text] [Related]

  • 15. Bulbocapnine is not a selective DA1 receptor antagonist.
    Kohli JD, Glock D, Goldberg LI.
    J Pharm Pharmacol; 1986 May 06; 38(5):401-2. PubMed ID: 2872323
    [Abstract] [Full Text] [Related]

  • 16. Role of dopamine and selective dopamine receptor agonists on mouse ductus arteriosus tone and responsiveness.
    Crockett SL, Harris M, Boatwright N, Su RL, Yarboro MT, Berger CD, Shelton EL, Reese J, Segar JL.
    Pediatr Res; 2020 May 06; 87(6):991-997. PubMed ID: 31816622
    [Abstract] [Full Text] [Related]

  • 17. The action of a dopamine (DA1) receptor agonist, fenoldopam in human vasculature in vivo and in vitro.
    Hughes A, Thom S, Martin G, Redman D, Hasan S, Sever P.
    Br J Clin Pharmacol; 1986 Nov 06; 22(5):535-40. PubMed ID: 2878679
    [Abstract] [Full Text] [Related]

  • 18. The natriuretic response to a dopamine DA1 agonist requires endogenous activation of dopamine DA2 receptors.
    Eklöf AC.
    Acta Physiol Scand; 1997 Aug 06; 160(4):311-4. PubMed ID: 9338511
    [Abstract] [Full Text] [Related]

  • 19. Activation of DA1 receptors by dopamine or fenoldopam increases cyclic AMP levels in the renal artery but not in the superior cervical ganglion of the rat.
    Alkadhi KA, Sabouni MH, Ansari AF, Lokhandwala MF.
    J Pharmacol Exp Ther; 1986 Aug 06; 238(2):547-53. PubMed ID: 2874213
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.